Leerink Partners Starts Rhythm Pharmaceuticals (RYTM) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St futures rebound as oil retreats, investors weigh US-Iran tensions
- Oil prices fall as markets weigh impact of US strikes on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Rhythm Pharmaceuticals (RYTM) PT Raised to $102 at Leerink Partners
July 9, 2025 4:18 PM EDTLeerink Partners analyst Faisal Khurshid raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $102.00 (from $88.00) while maintaining a Outperform rating.
The analyst comments "We are updating our estimates for RYTM following this morning's disclosure of bivamelagon Ph 2 data in acquired... More
